Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the clinical variation of molecular clusters and tumor-immune drivers in Waldenström’s macroglobulinemia (WM), highlighting findings from a study which used a multi-omics approach to characterize patients. Prof. Ansell explains how these clusters may play a role in disease progression and further comments on the role of the tumor immune microenvironment in WM. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.